Paediatric

Torre del Greco, Italy

Paediatric

Torre del Greco, Italy
SEARCH FILTERS
Time filter
Source Type

News Article | April 28, 2017
Site: www.eurekalert.org

There is an age-related decline in children's physical activity levels as they progress through primary school, according to a British Heart Foundation-funded study. Researchers at the University of Bristol found that children spent less time doing physical activity and spent more time sedentary from Year 1 (aged 5-6) to Year 4 (aged 8-9). Additionally, by the time they got to Year 4, around a third of boys and two thirds of girls aged eight to nine years old in the study were failing to meet Chief Medical Officer's (CMO) recommended physical activity guidelines of an hour of physical activity per day. Previous research has shown that low levels of physical activity in childhood can track into adulthood, suggesting that we should be doing more to ensure children keep active throughout their younger lives. In the study, published today in the International Journal of Behavioral Nutrition and Physical Activity, the researchers tracked the physical activity levels of 1,300 children in Year 1, aged 5-6, over a week. To track the children, the team used an accelerometer, a smart device which gives an accurate measurement of movement. They then tracked the same children three years later, when they were in Year 4 (aged 8-9), and compared the results. The levels of moderate-to-vigorous-intensity physical activity dropped by four per cent in boys, and eleven per cent in girls, but even more worryingly the sedentary time increased by 20 per cent in boys and 23 per cent in girls. Further examination of the data showed that 62.3 per cent of boys and 35 per cent of girls met the CMO's recommendation of an hour per day in Year 4, compared with 72.5 per cent and 53.7 per cent respectively in Year 1. Professor Russ Jago, Professor of Paediatric Physical Activity and Public Health at the University of Bristol, who led the study, said: "The results show a clear need to find ways to help children to be active throughout the primary school years. We need to get children active and then keep them active as they move through primary school. "To help us to do this we need to find the activities that children enjoy and foster as many opportunities within and outside of school to take part in activity across the day."


News Article | April 20, 2017
Site: www.prweb.com

The fundraiser for the BC Children’s Hospital is being held on April 20-22, 2017 in several locations. On Thursday April 20th it will be held from 11AM-5PM at the River Market 810 Quay Side Dr. New Westminister, and on Friday April 21 & 22 from 11AM-7PM at Lonsdale Quay Market 123 Carrie Cates Ct. North Vancouver. The BC Children’s Hospital provides care for the most seriously ill and injured children across British Columbia. They also have been accredited with exemplary standing. BC Children’s Hospital is Canada’s first Tele-Paediatric intensive care service unit and provides children with increased access to specialized care closer to their home community With the awareness of the innocence of a child, the physical, social development and emotional wellbeing that is much needed in their growth, Oliver Samante, a teacher and a master of junkology also known as Dr. Recycle, is leading the fundraiser for the children’s hospital in the support of these very special kids. With his passion for children and utilizing and creating practical objects and toys from recycled containers, cartons, jugs and boxes, he will be creating with children with recycled items where he makes toys and creates many items that are usable on April 20, 21 and 22. On April 22 which is Earth day he will be at the North Vancouver Quay. All that participate on those dates will be able to take their creations home with them. “It is an honour to serve alongside and support Oliver Samante in this cause for enriching and enhancing the lives of our children in the BC community so they can get the best quality care, equipment and medical attention because every child is our future”, says Inthirani Arul the founder of SoulPath Inc. In a world filled with possibilities and abundance many of our children are facing health related medical conditions that have impacted, debilitated or taken them off their course as children with normal healthy lives, many spend their days in a hospital bed or using other medical equipment for their mobility. With a future that sometimes is uncertain depending on the varying medical diagnosis they face, it is important to bring to the forefront that our children are our future and a social responsibility. This event shows families the additional needed support by coming together as a community. Join us for this fun, amazing and worthy cause and event, entry/participation by donation only. You can also find out more about Inthirani Arul by going to http://www.Soulpathinc.com.


LEESBURG, Va., May 03, 2017 (GLOBE NEWSWIRE) -- K2M Group Holdings, Inc. (NASDAQ:KTWO) (the "Company" or "K2M"), a global leader of complex spine and minimally invasive solutions focused on achieving three-dimensional Total Body Balance™, today announced that it will showcase the Balance ACS™ (or BACS™) platform at the 2017 combined meeting of The European Paediatric Orthopaedic Society and The Pediatric Orthopaedic Society of North America (EPOSNA) from May 3–6 in Barcelona, Spain, at Stand #13. The Company will also host a clinical symposium in 3D spinal solutions on May 4 in Sala H3. “K2M is excited to participate in this year’s EPOSNA, a keynote meeting encompassing the latest science, education, and advocacy to improve surgical care in children across Europe and North America with spinal deformities,” said K2M President and CEO, Eric Major. “We look forward to further introducing Balance ACS—a comprehensive platform of products, services, and research—to surgeons across Europe and North America. With BACS, our goal is to help surgeons holistically manage the entire patient experience over the full episodic care continuum, and ultimately, achieve Total Body Balance for spine patients.” Balance ACS provides solutions to balance the spine by addressing each anatomical vertebral segment with a 360-degree approach to the axial, coronal, and sagittal planes, emphasizing Total Body Balance as an important component of surgical success. During the meeting, K2M will demo the BACS System services offering—which includes BACS Preauthorization, BACS Surgical Planner, BACS Anatomical Models, and BACS Data Management—and the BACS app, a convenient portal for surgeons to access the BACS System. K2M will also host an interactive clinical symposium entitled: “Techniques to Optimize Spinal Balance” facilitated by Dennis P. Devito, MD, an orthopaedic surgeon and director of the Spine Program at Children’s Healthcare of Atlanta. The session will begin at 12:45 p.m. on May 4 in Sala H3. For more information about Balance ACS and K2M, visit www.BACS.com and www.K2M.com. K2M Group Holdings, Inc. is a global leader of complex spine and minimally invasive solutions focused on achieving three-dimensional Total Body Balance. Since its inception, K2M has designed, developed, and commercialized innovative complex spine and minimally invasive spine technologies and techniques used by spine surgeons to treat some of the most complicated spinal pathologies. K2M has leveraged these core competencies into Balance ACS, a platform of products, services, and research to help surgeons achieve three-dimensional spinal balance across the axial, coronal, and sagittal planes, with the goal of supporting the full continuum of care to facilitate quality patient outcomes. The Balance ACS platform, in combination with the Company’s technologies, techniques, and leadership in the 3D-printing of spinal devices, enable K2M to compete favorably in the global spinal surgery market. For more information, visit www.K2M.com and connect with us on Facebook, Twitter, Instagram, LinkedIn, and YouTube. This press release contains forward-looking statements that reflect current views with respect to, among other things, operations and financial performance.  Forward-looking statements include all statements that are not historical facts such as our statements about our expected financial results and guidance and our expectations for future business prospects. In some cases, you can identify these forward-looking statements by the use of words such as “outlook,” “guidance,” “believes,” “expects,” “potential,” “continues,” “may,” “will,” “should,” “could,” “seeks,” “predicts,” “intends,” “plans,” “estimates,” “anticipates” or the negative version of these words or other comparable words. Such forward-looking statements are subject to various risks and uncertainties including, among other things: our ability to achieve or sustain profitability in the future; our ability to demonstrate to spine surgeons the merits of our products; pricing pressures and our ability to compete effectively generally; collaboration and consolidation in hospital purchasing; inadequate coverage and reimbursement for our products from third-party payors; lack of long-term clinical data supporting the safety and efficacy of our products; dependence on a limited number of third-party suppliers; our ability to maintain and expand our network of direct sales employees, independent sales agencies and international distributors and their level of sales or distribution activity with respect to our products; proliferation of physician-owned distributorships in our industry; decline in the sale of certain key products; loss of key personnel; our ability to enhance our product offerings through research and development; our ability to manage expected growth; our ability to successfully acquire or invest in new or complementary businesses, products or technologies; our ability to educate surgeons on the safe and appropriate use of our products; costs associated with high levels of inventory; impairment of our goodwill and intangible assets; disruptions in our main facility or information technology systems;  our ability to ship a sufficient number of our products to meet demand; our ability to strengthen our brand; fluctuations in insurance cost and availability; our ability to comply with extensive governmental regulation within the United States and foreign jurisdictions; our ability  to maintain or obtain regulatory approvals and clearances within the United States and foreign jurisdictions; voluntary corrective actions by us or our distribution or other business partners or agency enforcement actions; recalls or serious safety issues with our products; enforcement actions by regulatory agencies for improper marketing or promotion; misuse or off-label use of our products; delays or failures in clinical trials and results of clinical trials; legal restrictions on our procurement, use, processing, manufacturing or distribution of allograft bone tissue; negative publicity concerning methods of tissue recovery and screening of donor tissue; costs and liabilities relating to environmental laws and regulations; our failure or the failure of our agents to comply with fraud and abuse laws; U.S. legislative or Food and Drug Administration regulatory reforms; adverse effects of medical device tax provisions; potential tax changes in jurisdictions in which we conduct business; our ability to generate significant sales; potential fluctuations in sales volumes and our results of operations over the course of the year; uncertainty in future capital needs and availability of capital to meet our needs; our level of indebtedness and the availability of borrowings under our credit facility; restrictive covenants and the impact of other provisions in the indenture governing our convertible senior notes and our credit facility; continuing worldwide economic instability; our ability to protect our intellectual property rights; patent litigation and product liability lawsuits; damages relating to trade secrets or non-competition or non-solicitation agreements; risks associated with operating internationally; fluctuations in foreign currency exchange rates; our ability to comply with the Foreign Corrupt Practices Act and similar laws; increased costs and additional regulations and requirements as a result of being a public company; our ability to implement and maintain effective internal control over financial reporting; potential volatility in our stock due to sales of additional shares by our pre-IPO owners or otherwise; our lack of current plans to pay cash dividends; our ability to take advantage of certain reduced disclosure requirements and exemptions as a result of being an emerging growth company; potential dilution by the future issuances of additional common stock in connection with our incentive plans, acquisitions or otherwise; anti-takeover provisions in our organizational documents and our ability to issue preferred stock without shareholder approval; potential limits on our ability to use our net operating loss carryforwards; and other risks and uncertainties, including those described under the section entitled “Risk Factors” in our most recent Annual Report on Form 10-K filed with the SEC, as such factors may be updated from time to time in our periodic filings with the SEC, which are accessible on the SEC’s website at www.sec.gov.  Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements.  These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and our filings with the SEC. We operate in a very competitive and challenging environment.  New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this release. We cannot assure you that the results, events and circumstances reflected in the forward-looking statements will be achieved or occur, and actual results, events or circumstances could differ materially from those described in the forward-looking statements. The forward-looking statements made in this press release relate only to events as of the date on which the statements are made. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Unless specifically stated otherwise, our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, investments or other strategic transactions we may make.


LEESBURG, Va., May 03, 2017 (GLOBE NEWSWIRE) -- K2M Group Holdings, Inc. (NASDAQ:KTWO) (the "Company" or "K2M"), a global leader of complex spine and minimally invasive solutions focused on achieving three-dimensional Total Body Balance™, today announced that it will showcase the Balance ACS™ (or BACS™) platform at the 2017 combined meeting of The European Paediatric Orthopaedic Society and The Pediatric Orthopaedic Society of North America (EPOSNA) from May 3–6 in Barcelona, Spain, at Stand #13. The Company will also host a clinical symposium in 3D spinal solutions on May 4 in Sala H3. “K2M is excited to participate in this year’s EPOSNA, a keynote meeting encompassing the latest science, education, and advocacy to improve surgical care in children across Europe and North America with spinal deformities,” said K2M President and CEO, Eric Major. “We look forward to further introducing Balance ACS—a comprehensive platform of products, services, and research—to surgeons across Europe and North America. With BACS, our goal is to help surgeons holistically manage the entire patient experience over the full episodic care continuum, and ultimately, achieve Total Body Balance for spine patients.” Balance ACS provides solutions to balance the spine by addressing each anatomical vertebral segment with a 360-degree approach to the axial, coronal, and sagittal planes, emphasizing Total Body Balance as an important component of surgical success. During the meeting, K2M will demo the BACS System services offering—which includes BACS Preauthorization, BACS Surgical Planner, BACS Anatomical Models, and BACS Data Management—and the BACS app, a convenient portal for surgeons to access the BACS System. K2M will also host an interactive clinical symposium entitled: “Techniques to Optimize Spinal Balance” facilitated by Dennis P. Devito, MD, an orthopaedic surgeon and director of the Spine Program at Children’s Healthcare of Atlanta. The session will begin at 12:45 p.m. on May 4 in Sala H3. For more information about Balance ACS and K2M, visit www.BACS.com and www.K2M.com. K2M Group Holdings, Inc. is a global leader of complex spine and minimally invasive solutions focused on achieving three-dimensional Total Body Balance. Since its inception, K2M has designed, developed, and commercialized innovative complex spine and minimally invasive spine technologies and techniques used by spine surgeons to treat some of the most complicated spinal pathologies. K2M has leveraged these core competencies into Balance ACS, a platform of products, services, and research to help surgeons achieve three-dimensional spinal balance across the axial, coronal, and sagittal planes, with the goal of supporting the full continuum of care to facilitate quality patient outcomes. The Balance ACS platform, in combination with the Company’s technologies, techniques, and leadership in the 3D-printing of spinal devices, enable K2M to compete favorably in the global spinal surgery market. For more information, visit www.K2M.com and connect with us on Facebook, Twitter, Instagram, LinkedIn, and YouTube. This press release contains forward-looking statements that reflect current views with respect to, among other things, operations and financial performance.  Forward-looking statements include all statements that are not historical facts such as our statements about our expected financial results and guidance and our expectations for future business prospects. In some cases, you can identify these forward-looking statements by the use of words such as “outlook,” “guidance,” “believes,” “expects,” “potential,” “continues,” “may,” “will,” “should,” “could,” “seeks,” “predicts,” “intends,” “plans,” “estimates,” “anticipates” or the negative version of these words or other comparable words. Such forward-looking statements are subject to various risks and uncertainties including, among other things: our ability to achieve or sustain profitability in the future; our ability to demonstrate to spine surgeons the merits of our products; pricing pressures and our ability to compete effectively generally; collaboration and consolidation in hospital purchasing; inadequate coverage and reimbursement for our products from third-party payors; lack of long-term clinical data supporting the safety and efficacy of our products; dependence on a limited number of third-party suppliers; our ability to maintain and expand our network of direct sales employees, independent sales agencies and international distributors and their level of sales or distribution activity with respect to our products; proliferation of physician-owned distributorships in our industry; decline in the sale of certain key products; loss of key personnel; our ability to enhance our product offerings through research and development; our ability to manage expected growth; our ability to successfully acquire or invest in new or complementary businesses, products or technologies; our ability to educate surgeons on the safe and appropriate use of our products; costs associated with high levels of inventory; impairment of our goodwill and intangible assets; disruptions in our main facility or information technology systems;  our ability to ship a sufficient number of our products to meet demand; our ability to strengthen our brand; fluctuations in insurance cost and availability; our ability to comply with extensive governmental regulation within the United States and foreign jurisdictions; our ability  to maintain or obtain regulatory approvals and clearances within the United States and foreign jurisdictions; voluntary corrective actions by us or our distribution or other business partners or agency enforcement actions; recalls or serious safety issues with our products; enforcement actions by regulatory agencies for improper marketing or promotion; misuse or off-label use of our products; delays or failures in clinical trials and results of clinical trials; legal restrictions on our procurement, use, processing, manufacturing or distribution of allograft bone tissue; negative publicity concerning methods of tissue recovery and screening of donor tissue; costs and liabilities relating to environmental laws and regulations; our failure or the failure of our agents to comply with fraud and abuse laws; U.S. legislative or Food and Drug Administration regulatory reforms; adverse effects of medical device tax provisions; potential tax changes in jurisdictions in which we conduct business; our ability to generate significant sales; potential fluctuations in sales volumes and our results of operations over the course of the year; uncertainty in future capital needs and availability of capital to meet our needs; our level of indebtedness and the availability of borrowings under our credit facility; restrictive covenants and the impact of other provisions in the indenture governing our convertible senior notes and our credit facility; continuing worldwide economic instability; our ability to protect our intellectual property rights; patent litigation and product liability lawsuits; damages relating to trade secrets or non-competition or non-solicitation agreements; risks associated with operating internationally; fluctuations in foreign currency exchange rates; our ability to comply with the Foreign Corrupt Practices Act and similar laws; increased costs and additional regulations and requirements as a result of being a public company; our ability to implement and maintain effective internal control over financial reporting; potential volatility in our stock due to sales of additional shares by our pre-IPO owners or otherwise; our lack of current plans to pay cash dividends; our ability to take advantage of certain reduced disclosure requirements and exemptions as a result of being an emerging growth company; potential dilution by the future issuances of additional common stock in connection with our incentive plans, acquisitions or otherwise; anti-takeover provisions in our organizational documents and our ability to issue preferred stock without shareholder approval; potential limits on our ability to use our net operating loss carryforwards; and other risks and uncertainties, including those described under the section entitled “Risk Factors” in our most recent Annual Report on Form 10-K filed with the SEC, as such factors may be updated from time to time in our periodic filings with the SEC, which are accessible on the SEC’s website at www.sec.gov.  Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements.  These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and our filings with the SEC. We operate in a very competitive and challenging environment.  New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this release. We cannot assure you that the results, events and circumstances reflected in the forward-looking statements will be achieved or occur, and actual results, events or circumstances could differ materially from those described in the forward-looking statements. The forward-looking statements made in this press release relate only to events as of the date on which the statements are made. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Unless specifically stated otherwise, our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, investments or other strategic transactions we may make.


LEESBURG, Va., May 03, 2017 (GLOBE NEWSWIRE) -- K2M Group Holdings, Inc. (NASDAQ:KTWO) (the "Company" or "K2M"), a global leader of complex spine and minimally invasive solutions focused on achieving three-dimensional Total Body Balance™, today announced that it will showcase the Balance ACS™ (or BACS™) platform at the 2017 combined meeting of The European Paediatric Orthopaedic Society and The Pediatric Orthopaedic Society of North America (EPOSNA) from May 3–6 in Barcelona, Spain, at Stand #13. The Company will also host a clinical symposium in 3D spinal solutions on May 4 in Sala H3. “K2M is excited to participate in this year’s EPOSNA, a keynote meeting encompassing the latest science, education, and advocacy to improve surgical care in children across Europe and North America with spinal deformities,” said K2M President and CEO, Eric Major. “We look forward to further introducing Balance ACS—a comprehensive platform of products, services, and research—to surgeons across Europe and North America. With BACS, our goal is to help surgeons holistically manage the entire patient experience over the full episodic care continuum, and ultimately, achieve Total Body Balance for spine patients.” Balance ACS provides solutions to balance the spine by addressing each anatomical vertebral segment with a 360-degree approach to the axial, coronal, and sagittal planes, emphasizing Total Body Balance as an important component of surgical success. During the meeting, K2M will demo the BACS System services offering—which includes BACS Preauthorization, BACS Surgical Planner, BACS Anatomical Models, and BACS Data Management—and the BACS app, a convenient portal for surgeons to access the BACS System. K2M will also host an interactive clinical symposium entitled: “Techniques to Optimize Spinal Balance” facilitated by Dennis P. Devito, MD, an orthopaedic surgeon and director of the Spine Program at Children’s Healthcare of Atlanta. The session will begin at 12:45 p.m. on May 4 in Sala H3. For more information about Balance ACS and K2M, visit www.BACS.com and www.K2M.com. K2M Group Holdings, Inc. is a global leader of complex spine and minimally invasive solutions focused on achieving three-dimensional Total Body Balance. Since its inception, K2M has designed, developed, and commercialized innovative complex spine and minimally invasive spine technologies and techniques used by spine surgeons to treat some of the most complicated spinal pathologies. K2M has leveraged these core competencies into Balance ACS, a platform of products, services, and research to help surgeons achieve three-dimensional spinal balance across the axial, coronal, and sagittal planes, with the goal of supporting the full continuum of care to facilitate quality patient outcomes. The Balance ACS platform, in combination with the Company’s technologies, techniques, and leadership in the 3D-printing of spinal devices, enable K2M to compete favorably in the global spinal surgery market. For more information, visit www.K2M.com and connect with us on Facebook, Twitter, Instagram, LinkedIn, and YouTube. This press release contains forward-looking statements that reflect current views with respect to, among other things, operations and financial performance.  Forward-looking statements include all statements that are not historical facts such as our statements about our expected financial results and guidance and our expectations for future business prospects. In some cases, you can identify these forward-looking statements by the use of words such as “outlook,” “guidance,” “believes,” “expects,” “potential,” “continues,” “may,” “will,” “should,” “could,” “seeks,” “predicts,” “intends,” “plans,” “estimates,” “anticipates” or the negative version of these words or other comparable words. Such forward-looking statements are subject to various risks and uncertainties including, among other things: our ability to achieve or sustain profitability in the future; our ability to demonstrate to spine surgeons the merits of our products; pricing pressures and our ability to compete effectively generally; collaboration and consolidation in hospital purchasing; inadequate coverage and reimbursement for our products from third-party payors; lack of long-term clinical data supporting the safety and efficacy of our products; dependence on a limited number of third-party suppliers; our ability to maintain and expand our network of direct sales employees, independent sales agencies and international distributors and their level of sales or distribution activity with respect to our products; proliferation of physician-owned distributorships in our industry; decline in the sale of certain key products; loss of key personnel; our ability to enhance our product offerings through research and development; our ability to manage expected growth; our ability to successfully acquire or invest in new or complementary businesses, products or technologies; our ability to educate surgeons on the safe and appropriate use of our products; costs associated with high levels of inventory; impairment of our goodwill and intangible assets; disruptions in our main facility or information technology systems;  our ability to ship a sufficient number of our products to meet demand; our ability to strengthen our brand; fluctuations in insurance cost and availability; our ability to comply with extensive governmental regulation within the United States and foreign jurisdictions; our ability  to maintain or obtain regulatory approvals and clearances within the United States and foreign jurisdictions; voluntary corrective actions by us or our distribution or other business partners or agency enforcement actions; recalls or serious safety issues with our products; enforcement actions by regulatory agencies for improper marketing or promotion; misuse or off-label use of our products; delays or failures in clinical trials and results of clinical trials; legal restrictions on our procurement, use, processing, manufacturing or distribution of allograft bone tissue; negative publicity concerning methods of tissue recovery and screening of donor tissue; costs and liabilities relating to environmental laws and regulations; our failure or the failure of our agents to comply with fraud and abuse laws; U.S. legislative or Food and Drug Administration regulatory reforms; adverse effects of medical device tax provisions; potential tax changes in jurisdictions in which we conduct business; our ability to generate significant sales; potential fluctuations in sales volumes and our results of operations over the course of the year; uncertainty in future capital needs and availability of capital to meet our needs; our level of indebtedness and the availability of borrowings under our credit facility; restrictive covenants and the impact of other provisions in the indenture governing our convertible senior notes and our credit facility; continuing worldwide economic instability; our ability to protect our intellectual property rights; patent litigation and product liability lawsuits; damages relating to trade secrets or non-competition or non-solicitation agreements; risks associated with operating internationally; fluctuations in foreign currency exchange rates; our ability to comply with the Foreign Corrupt Practices Act and similar laws; increased costs and additional regulations and requirements as a result of being a public company; our ability to implement and maintain effective internal control over financial reporting; potential volatility in our stock due to sales of additional shares by our pre-IPO owners or otherwise; our lack of current plans to pay cash dividends; our ability to take advantage of certain reduced disclosure requirements and exemptions as a result of being an emerging growth company; potential dilution by the future issuances of additional common stock in connection with our incentive plans, acquisitions or otherwise; anti-takeover provisions in our organizational documents and our ability to issue preferred stock without shareholder approval; potential limits on our ability to use our net operating loss carryforwards; and other risks and uncertainties, including those described under the section entitled “Risk Factors” in our most recent Annual Report on Form 10-K filed with the SEC, as such factors may be updated from time to time in our periodic filings with the SEC, which are accessible on the SEC’s website at www.sec.gov.  Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements.  These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and our filings with the SEC. We operate in a very competitive and challenging environment.  New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this release. We cannot assure you that the results, events and circumstances reflected in the forward-looking statements will be achieved or occur, and actual results, events or circumstances could differ materially from those described in the forward-looking statements. The forward-looking statements made in this press release relate only to events as of the date on which the statements are made. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Unless specifically stated otherwise, our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, investments or other strategic transactions we may make.


(Prague, May 13, 2017) The results from a Norwegian study show that a new genetic test for characterising intestinal microbiota may help to diagnose inflammatory bowel disease (IBD) in children and predict which children will develop the most extensive disease and need early, aggressive intervention. Researchers from Oslo, Norway today presented the results of a study that evaluated faecal microbiota profiles in more than 100 newly-diagnosed children with IBD and found a clear distinction between the profiles of these children and a healthy comparator group (1). The researchers also found that children with the most disturbed microbiota profiles (dysbiosis) had the most extensive IBD and were more likely to need biological therapy in the future. Speaking at the annual meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) in Prague, lead researcher, Dr Christine Olbjørn from the Department of Paediatric and Adolescent Medicine at Akershus University Hospital in Oslo said the study indicates that this type of profiling could be clinically useful in paediatric practice and long-term patient care. "IBD is often far more aggressive in children than it is in adults but it is very difficult to predict the individual disease course" she said. "We and other researchers are interested in the potential of faecal microbiota profiling to help us diagnose and manage these children and we have been helped by the availability of new genetic tests that can quantify different bacterial species in the gut." To undertake the study, Dr Olbjørn and colleagues from other specialist centres in Norway collected faecal samples from 235 children and adolescents (80 children with Crohn's disease, 27 with ulcerative colitis, three with unclassified IBD, 50 with symptoms, but no IBD diagnosis, and 75 healthy children). The samples were analysed using a new test called the GA-map™ IBD Dysbiosis Test (2), which uses advanced DNA profiling to identify up to 300 different bacteria on different taxonomic levels. The microbiota profiles were then compared between the children with IBD, those with symptoms but no IBD diagnosis, and healthy children. "We found that the probe signal intensity, which indicates the abundance of different bacterial species, was significantly reduced in the children with IBD and those with symptoms, but no IBD, compared to the healthy children", explained Dr Olbjørn. "What was perhaps more intriguing was that the children with more extensive IBD had significantly more Clostridiales, and those with extensive Crohn's disease had more Proteobacteria than children with limited disease. Children who were subsequently treated with TNF blockers had a lower diversity of Firmicutes, Tenericutes and Bacteroidetes as well as lower abundance of Actinobacteria before treatment than those who were ultimately treated with conventional medications." Dr Olbjørn believes that the results of this study add further support to the view that gut microbial dysbiosis play a key role in the pathogenesis of IBD in children. "Our findings suggest that faecal microbiota profiles may be used to identify which children are destined for a more severe form of IBD and which, therefore, need more intensive monitoring and possibly earlier, more aggressive treatment." For further information, or to speak to an ESPGHAN expert, please email media@espghan.org or call James M. Butcher on +44 (0) 1444 811 099. Download an infographic on Paediatric IBD here: http://www. Dr Olbjørn is a paediatric gastroenterologist, and has worked as a consultant at Akershus University Hospital outside of Oslo for several years. Her main interest is IBD- from diagnosis, treatment and follow-up, including transition of care from adolescence to adulthood. She is currently teaching medical students in paediatrics and working on her PhD thesis which elaborates on prognosis in IBD and how to improve individualised and personalised care. The European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) is a multi-professional organisation whose aim is to promote the health of children with special attention to the gastrointestinal tract, liver and nutritional status, through knowledge creation, the dissemination of science based information, the promotion of best practice in the delivery of care and the provision of high quality education for paediatric gastroenterology, hepatology and nutrition professionals in Europe and beyond. Find out more by visiting http://www. About the 50th Annual Meeting of ESPGHAN The 50th Annual Meeting of ESPGHAN is taking place from Wednesday 10 to Saturday 13 May 2017, in Prague, Czech Republic. Every year the ESPGHAN meeting attracts the key opinion leaders in the field of Paediatric Gastroenterology, Hepatology and Nutrition from across Europe and all five continents, turning it into the largest conference of its kind worldwide. The Annual Meeting attracts over 4,000 experts from over 100 countries, all operating in the fields of Paediatric Gastroenterology, Hepatology and Nutrition, turning it into the largest conference of its kind worldwide. This year the meeting has received a record number of 839 accepted abstracts. 1. Olbjørn C, Småstuen MC, Thiis-Evensen E et al. Faecal microbiota profiles at diagnosis in paediatric inflammatory bowel disease. Prediction of disease severity and subsequent need of biologic therapy. Presented at the Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. Prague, Czech Republic, 13 May, 2017. 2. Casén C, Vebø HC, Sekelja M et al. Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD. Aliment Pharmacol Ther 2015;42(1):71-83.


News Article | May 11, 2017
Site: www.eurekalert.org

(Prague, 11 May, 2017) Experts at the 50th Annual Meeting of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) are today warning that young children who follow a vegan diet without medical and dietary advice carry the risk of a number of nutrient deficiencies, including vitamin B12, calcium, zinc and high quality protein, which can have potentially devastating health effects. Studies have shown that children who follow a vegan diet are leaner and smaller than those children who consume meat or those who have vegetarian diets. "It is difficult to ensure a healthy and balanced vegan diet in young infants, and parents should understand the serious consequences of failing to follow advice regarding supplementation of the diet. The risks of getting it wrong can include irreversible cognitive damage and, in the extreme, death. Our advice is that if parents pursue a vegan diet for their child, they must seek and strictly follow medical and dietary advice to make sure their infant receives adequate nutrition. Both mother and infant should follow advice regarding supplementation" advises Professor Mary Fewtrell, chairman of ESPGHAN's nutrition committee comments: The biggest risk to vegan children is that of vitamin B12 deficiency. Foods derived from animals have been shown to be the only reliable source of vitamin B12 and a deficiency of the vitamin can have devastating effects. Vitamin B12 is essential to the creation of DNA, indispensable for the maintenance of the nervous system, and a lack of it can result in haematological and neurological disorders, causing damage in young children which can be irreversible. Presenting to healthcare professionals at the ESPGHAN conference today, Professor Myriam Van Winckel said: "The more restricted the diet of the child, the greater the risk of deficiency and this is by far highest in vegan children, but the risk does not stop there. Vegan mothers who breastfeed also need to be aware that their children can develop vitamin B12 deficiency between 2 and 12 months because of the lack of reserves in their body at birth, even if the mother is not showing any signs of deficiency herself." Infants on vegan diets are also at risk of protein and calcium malnutrition, a situation made worse because parents can be misled by milk supplements. Rice milk, almond milk and soy milk suggest that they are suitable substitutes for milk, but experts say these should be properly labelled as 'drinks', because their nutritional value is not comparable to milk. Maintaining healthy levels of calcium is important for ensuring lifelong normal bone density, and rickets has been found in toddlers on a calcium-deficient diet consuming large amounts of non-supplemented soy drink. However, unlike vegan diets, varied lacto (ovo) vegetarian and semi-vegetarian diets are generally safe. Although long term follow-up studies are scarce, they do not show a detrimental effect of vegetarian diets in children but instead point to beneficial health outcomes compared to omnivore diets, such as favourable lipid profile, antioxidant status, dietary fiber intake as well as tendencies towards a lower risk of being overweight. For further information, or to speak to an expert, please email media@espghan.org or call James M. Butcher at ESPGHAN's official press agency, Spink, on +44 (0) 1444 811 099. Myriam Van Winckel is head of paediatric gastroenterology at the University Hospital Ghent, Belgium. Her areas of interest include paediatric gastroenterology, hepatology and nutrition and parenteral nutrition and enteral feeding in children. Mary Fewtrell is Professor of Paediatric Nutrition at University College London and specialises in the nutritional programming of bone health, body composition and obesity, human lactation and the design of infant formula, complementary feeding and the duration of exclusive breastfeeding, and infant growth and its association with later-life health. She is also the Chair of ESPGHAN's Nutrition Committee. The European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) is a multi-professional organisation whose aim is to promote the health of children with special attention to the gastrointestinal tract, liver and nutritional status, through knowledge creation, the dissemination of science based information, the promotion of best practice in the delivery of care and the provision of high quality education for paediatric gastroenterology, hepatology and nutrition professionals in Europe and beyond. Find out more by visiting http://www. The 50th Annual Meeting of ESPGHAN is taking place from Wednesday 10 to Saturday 13 May 2017, in Prague, Czech Republic. Every year the ESPGHAN meeting attracts the key opinion leaders in the field of Paediatric Gastroenterology, Hepatology and Nutrition from across Europe and all five continents, turning it into the largest conference of its kind worldwide. The Annual Meeting attracts over 4,000 experts from over 100 countries, all operating in the fields of Paediatric Gastroenterology, Hepatology and Nutrition, turning it into the largest conference of its kind worldwide. This year the meeting has received a record number of 839 accepted abstracts. Fewtrell, M., Bronsky, J. et al. Complementary Feeding: A Position Paper by the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Committee on Nutrition. JPGN. 2017. V. 64. No. 1. pp. 119-132. Van Winckel, M. Vegetarian and vegan diets; pros and cons in infants, children and adolescents. Presented at the Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. Prague, Czech Republic, 11 May, 2017. Van Winckel, M., Vande Velde, S. et al. Clinical practice: Vegetarian infant and child nutrition. European Journal of Pediatrics. 2011. V. 170. No. 12. pp. 1489-1494.


News Article | May 8, 2017
Site: www.prnewswire.com

This program will focus on training in six subspecialties of ophthalmology including glaucoma, retina, retinopathy of prematurity (ROP), oculoplastics, pediatric cataract and strabismus. Orbis will also train the staff at the eye clinic at CTCH to screen for common eye problems seen in children in the region, including premature babies at risk of ROP—a disease that can lead to permanent blindness and is on the rise in middle-income countries like Vietnam 1. Children with more complex eye problems will be transferred to CTEH for further treatment and follow-up care if required. By leveraging the high-profile Flying Eye Hospital, the Can Tho program also helps raise awareness of the prevention and early detection of childhood blindness among the general public in the Mekong Delta region, where Can Tho is located. The Mekong Delta has a large population of around 17.5 million people in southern Vietnam2, but its rural areas are among some of the most under-resourced communities in the country. Natural disasters often affect the livelihood of local people, and pediatric eye care services are almost non-existent. It is estimated that 300,000 children in the Mekong Delta region have eye diseases3 which could otherwise prevent permanent vision loss. Treating children for eye diseases is very different from treating adults. Children's eyes are not just smaller, but they require special, trained surgical techniques, including nursing and anesthesia. Although significant progress has been made to address avoidable blindness (low vision or blindness that could be otherwise prevented or cured by known, cost-effective means) in adults in recent years, there is a shortage of trained pediatric ophthalmologists to meet the needs of the 3 million visually impaired children in the country 4. Anesthesia requirements and the need for better pediatric follow-up care remain challenging in the country, especially in the Mekong Delta region. "We are delighted to be back in Vietnam, working with the government and our partners to continue to help build capacity to prevent and manage childhood blindness," said Dr. Jonathan Lord, Orbis Global Medical Director. "We have set up six pediatric eye centers in Hanoi, Hue, Da Nang, Ho Chi Minh City, and recently in Can Tho and Binh Dinh. Our long-term goal is to develop Can Tho into a pediatric eye care hub for patients in the Mekong Delta, and progress is already underway." "Orbis began working with Vietnam's ophthalmic communities through hospital-based projects in 1996, and later a permanent office was established in Hanoi in 2003," said Huong Tran, Country Director of Orbis in Vietnam. About Orbis  Orbis is a leading global non-governmental organization that has been a pioneer in the prevention and treatment of blindness for over 30 years. Orbis transforms lives by delivering the skills, resources and knowledge needed to deliver accessible quality eye care. Working in collaboration with local partners including hospitals, universities, government agencies and ministries of health, Orbis provides hands-on ophthalmology training, strengthens healthcare infrastructure and advocates for making eye health a priority. Orbis operates the world's only Flying Eye Hospital, a fully accredited ophthalmic teaching hospital on board an MD-10 aircraft. To learn more, please visit orbis.org. 1 WHO: Prevention of Blindness and Visual Impairment: Priority eye diseases – childhood blindness, from http://www.who.int/blindness/causes/priority/en/index3.html 2 General Statistics Office, Statistical Handbook of Vietnam, Hanoi: Statistical Publishing House, 2014 3 Health Policy and Strategy Institute, Situation Analysis and Paediatric Eye Care in Vietnam, 2014 4 The Rapid Assessment of Avoidable Blindness (RAAB) study, 2007 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/orbiss-flying-eye-hospital-lands-in-vietnam-300453532.html


News Article | May 29, 2017
Site: www.eurekalert.org

A new study highlights that children suffering from inflammatory bowel disease (IBD) are not meeting the daily recommended intake of calcium and vitamin D. The research, conducted at Great Ormond Street Hospital for Children in London, identified that only 26.6% and 21.3% of paediatric IBD patients were achieving the current recommended intake for calcium and vitamin D respectively. Medical experts from United European Gastroenterology (UEG) are therefore calling for immediate intervention to ensure that paediatric IBD patients are not put at risk of experiencing poor bone health and development, calcium homeostasis imbalance and vitamin D deficiencies. Achieving optimal levels of calcium and vitamin D is essential for developing children, especially in patients with IBD, as research suggests that children and adolescents with the disease develop suboptimal bone health in comparison to their peers. Therefore, they may not achieve optimal bone mineralisation, resulting in an increased risk of permanent height deficits. Vitamin D and calcium both play a major role in bone health and recently vitamin D has shown to potentiate the effect of anti-inflammatory treatments. However, ensuring a sufficient intake of vitamin D and calcium in children can be challenging. Rita Shergill-Bonner, Principle Dietician at Great Ormond Street Hospital for Children, London, explains, "When taking into account their young age and modern eating habits, coupled with the emotional, psychological and physical stress of living with IBD, it can be hard for paediatric patients to maintain a balanced diet and a sufficient intake of the right nutrients. We therefore urge the parents and carers of paediatric IBD patients to monitor their children's diets carefully to ensure they are consuming the right foods to help their disease course and ensure adequate and normal development." There is no solitary cause of IBD but it is thought to be due to a combination of genetic and environmental factors. Incidence rates have been steadily increasing over the past few decades and one in four cases of the disease are diagnosed during childhood. Physical IBD symptoms can be extremely debilitating, including severe abdominal pain, diarrhoea, weight loss and fatigue. The disease can also have a significant impact on a patient's psychological, emotional and mental health, with over half of sufferers feeling that the disease negatively affects their education. Professor Philippe van Hootegem, UEG IBD expert comments, "There are many effective drugs available to help treat IBD but there are still a lot of unmet needs in both child and adult patients. Interesting and hopeful new drugs, some of which are to be taken orally, are in their final development stage. Nevertheless, a definitive curative therapy is not on the horizon yet and future research is still needed." "It is imperative that healthcare professionals provide all IBD patients with regular and frequent advice on nutrition and healthy eating habits, including guidance on food sources that are rich in calcium and vitamin D", adds Professor Gigi Veereman, UEG paediatric IBD expert. "Tailored care services, long-term follow up, regular reviews and frequent medical interventions are required to minimise additional health risk in our paediatric patients" May 29th is World Digestive Health Day and this year health organisations from around the world are coming together to highlight the issues affecting patients living with IBD. For further information and to schedule an interview with Professor Philippe van Hootegem, Professor Gigi Veereman or Rita Shergill-Bonner, please email media@ueg.eu or phone Luke Paskins on +44 (0)1444 811099 Professor Philippe van Hootegem is a member of the UEG Public Affairs Committee and a Consultant Gastroenterologist at the Sint-Lucas General Hospital, Bruges, Belgium. Professor Gigi Veereman is a member of the UEG Public Affairs Committee and a Paediatric Gastroenterologist at the University Hospital, Brussels, Belgium. Rita Shergill-Bonner is a Principle Gastroenterology Dietician at Great Ormond Street Hospital for Children, London, England. UEG, or United European Gastroenterology, is a professional non-profit organisation combining all the leading European societies concerned with digestive diseases. Together, its member societies represent over 22,000 specialists, working across medicine, surgery, paediatrics, gastrointestinal oncology and endoscopy. This makes UEG the most comprehensive organisation of its kind in the world, and a unique platform for collaboration and the exchange of knowledge. Find out more by visiting http://www. To advance standards of gastroenterological care and knowledge across Europe and the world, UEG offers numerous activities and initiatives, including: 1. Shergill-Bonner R., et al. Paediatric IBD patients do not meet the daily recommendations of vitamin D and calcium intake: survey based analysis in a tertiary centre. Presented at the 12th Congress of ECCO, Barcelona, February 15-18, 2017. Available here: https:/ 2. B. Wilson, S. Lönnfors, S. Vermeire. The true impact of IBD: a European Crohn's and Ulcerative Colitis patient life. IMPACT Survey 2010-2011. Available here: http://www.


News Article | May 11, 2017
Site: www.prweb.com

OrthoPediatrics Corp. was a Double Diamond sponsor of the 2017 combined EPOSNA meeting, which took place May 3 – 6 in Barcelona, Spain. This was a joint meeting of the European Paediatric Orthopaedic Society (EPOS) and the Pediatric Orthopedic Society of North America (POSNA). Over 1300 Pediatric Orthopedic Surgeons from across the United States and Europe participated in the program. OrthoPediatrics has been a leading sponsor of both organizations since the company’s inception. During the meeting, OrthoPediatrics also sponsored a lunch symposium titled “Modern Approaches to the Treatment of Complex Hip Disease”, featuring an international panel of key opinion leaders. Moderated by Dr. Pablo Castañada and Dr. Rudolf Ganger, panelists discussed diagnoses, pre-operative planning, and surgical techniques for the treatment of complex hip disease in children and adolescents. OrthoPediatrics’ CEO, Mark Throdahl said, “Our support of EPOS and POSNA, which is out of all proportion to our size, sets the priority for everything else we do. It builds corporate character and keeps us true to the cause of helping children throughout the world.” About OrthoPediatrics Corp. Founded in 2006, OrthoPediatrics is the only orthopedic company focused exclusively on providing a comprehensive product offering to the pediatric orthopedic market in order to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets 19 surgical systems that serve three of the largest categories within the pediatric orthopedic market. This offering spans trauma and deformity, complex spine and ACL reconstruction procedures. OrthoPediatrics also has the only global sales organization focused exclusively on pediatric orthopedics and distributes its products to 34 countries outside the United States.

Loading Paediatric collaborators
Loading Paediatric collaborators